PL2616444T3 - Związki będące modulatorami zmutowanego białka CFTR oraz ich zastosowanie w leczeniu chorób związanych z zaburzeniami w funkcjonowaniu białka CFTR - Google Patents

Związki będące modulatorami zmutowanego białka CFTR oraz ich zastosowanie w leczeniu chorób związanych z zaburzeniami w funkcjonowaniu białka CFTR

Info

Publication number
PL2616444T3
PL2616444T3 PL11736202T PL11736202T PL2616444T3 PL 2616444 T3 PL2616444 T3 PL 2616444T3 PL 11736202 T PL11736202 T PL 11736202T PL 11736202 T PL11736202 T PL 11736202T PL 2616444 T3 PL2616444 T3 PL 2616444T3
Authority
PL
Poland
Prior art keywords
cftr protein
modulators
compounds
diseases associated
treating diseases
Prior art date
Application number
PL11736202T
Other languages
English (en)
Inventor
Norbert Odolczyk
Piotr Zielenkiewicz
Grzegorz Wieczorek
Aleksander Edelman
Danielle Tondelier
Janine Fritsch
Original Assignee
Inst Biochemii I Biofizyki Pan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL392397A external-priority patent/PL221889B1/pl
Priority claimed from PL392396A external-priority patent/PL223680B1/pl
Application filed by Inst Biochemii I Biofizyki Pan filed Critical Inst Biochemii I Biofizyki Pan
Publication of PL2616444T3 publication Critical patent/PL2616444T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/304—Aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/305—Poly(thio)phosphinic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL11736202T 2010-09-14 2011-06-20 Związki będące modulatorami zmutowanego białka CFTR oraz ich zastosowanie w leczeniu chorób związanych z zaburzeniami w funkcjonowaniu białka CFTR PL2616444T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PL392397A PL221889B1 (pl) 2010-09-14 2010-09-14 Zastosowanie modulatora funkcji zmutowanego białka CFTR lub jego farmaceutycznie akceptowalnej pochodnej do wytwarzania leku do leczenia mukowiscydozy
PL392396A PL223680B1 (pl) 2010-09-14 2010-09-14 Zastosowanie modulatora funkcji zmutowanego białka CFTR
EP11736202.0A EP2616444B1 (en) 2010-09-14 2011-06-20 Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction
PCT/PL2011/000060 WO2012036573A2 (en) 2010-09-14 2011-06-20 Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction

Publications (1)

Publication Number Publication Date
PL2616444T3 true PL2616444T3 (pl) 2016-04-29

Family

ID=44356169

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11736202T PL2616444T3 (pl) 2010-09-14 2011-06-20 Związki będące modulatorami zmutowanego białka CFTR oraz ich zastosowanie w leczeniu chorób związanych z zaburzeniami w funkcjonowaniu białka CFTR

Country Status (19)

Country Link
US (5) US20130303761A1 (pl)
EP (4) EP2616444B1 (pl)
JP (3) JP5926731B2 (pl)
KR (1) KR20140023866A (pl)
CN (4) CN103228632B (pl)
AU (1) AU2011302715B2 (pl)
CA (1) CA2811265C (pl)
CY (1) CY1117249T1 (pl)
DK (1) DK2616444T3 (pl)
ES (1) ES2553628T3 (pl)
HR (1) HRP20151224T1 (pl)
HU (1) HUE026271T2 (pl)
IL (4) IL225166A (pl)
MX (2) MX2013002895A (pl)
NZ (3) NZ700827A (pl)
PL (1) PL2616444T3 (pl)
PT (1) PT2616444E (pl)
SI (1) SI2616444T1 (pl)
WO (1) WO2012036573A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2616444T3 (pl) * 2010-09-14 2016-04-29 Inst Biochemii I Biofizyki Pan Związki będące modulatorami zmutowanego białka CFTR oraz ich zastosowanie w leczeniu chorób związanych z zaburzeniami w funkcjonowaniu białka CFTR
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2017062422A1 (en) * 2015-10-07 2017-04-13 The Research Foundation For The State University Of New York METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXβ REDUCTASE
RU2724345C2 (ru) * 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
WO2017187274A1 (en) * 2016-04-29 2017-11-02 Institut Pasteur Methods and compositions for modifying cystic fibrosis transmembrane conductance regulator activity
CA3023512A1 (en) * 2016-05-09 2017-11-16 Proteostasis Therapeutics, Inc. Methods of identifying cftr modulators
MX2021012105A (es) 2019-04-03 2021-11-03 Aligos Therapeutics Inc Compuestos de pirrol.
US20220306603A1 (en) * 2019-06-12 2022-09-29 The Governors Of The University Of Alberta Targeting dna repair in tumor cells via inhibition of ercc1-xpf
AU2020311940A1 (en) 2019-07-11 2022-02-03 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
GB201916071D0 (en) * 2019-11-05 2019-12-18 Univ Bristol Treatment for nephrotic syndrome
JP7495313B2 (ja) 2020-09-23 2024-06-04 株式会社Subaru 車両用エアガイド

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3770514A (en) * 1972-06-08 1973-11-06 American Cyanamid Co Chemical treatment of metal
US5434086A (en) * 1989-08-22 1995-07-18 The Regents Of The University Of Michigan Method of testing potential cystic fibrosis treating compounds using cells in culture
US5948814A (en) 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
GB9909135D0 (en) * 1999-04-22 1999-06-16 Univ Wales Medicine Cystic fibrosis medicaments
GB2359078A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0017083D0 (en) 2000-07-13 2000-08-30 Univ Bristol Activation of the cystic fibrosis transmembrane conductive regulator chloride channel
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
LT2502911T (lt) * 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
WO2006015369A2 (en) * 2004-08-03 2006-02-09 The Johns Hopkins University Assays for identification of topoisomerase inhibitors
CA2600869A1 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
CA2634113A1 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
US20100047783A1 (en) * 2006-06-20 2010-02-25 El-Diery Wafik S Small molecule modulators of p53 family signaling
CA2668305C (en) * 2006-11-03 2017-01-03 Vertex Pharmaceuticals Incorporated Azaindole derivatives as cftr modulators
WO2008122038A1 (en) * 2007-04-02 2008-10-09 President And Fellows Of Harvard College Regulating autophagy
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
US8389736B2 (en) 2007-10-16 2013-03-05 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
WO2009051910A1 (en) 2007-10-16 2009-04-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
EP2364086B1 (en) * 2008-11-20 2016-09-14 Glsynthesis Inc. Novel antithrombotic diadenosine tetraphosphates and related analogs
PL2616444T3 (pl) * 2010-09-14 2016-04-29 Inst Biochemii I Biofizyki Pan Związki będące modulatorami zmutowanego białka CFTR oraz ich zastosowanie w leczeniu chorób związanych z zaburzeniami w funkcjonowaniu białka CFTR

Also Published As

Publication number Publication date
CY1117249T1 (el) 2017-04-05
NZ700827A (en) 2016-05-27
IL225166A (en) 2016-08-31
CN103228632B (zh) 2016-08-31
EP2816034B1 (en) 2018-12-12
JP2016028044A (ja) 2016-02-25
EP2616444B1 (en) 2015-08-26
JP2016029044A (ja) 2016-03-03
IL235013A0 (en) 2014-11-30
US20160113896A1 (en) 2016-04-28
AU2011302715A1 (en) 2013-05-02
DK2616444T3 (en) 2015-11-30
US20160101107A1 (en) 2016-04-14
EP2816035A3 (en) 2015-02-25
CN104496840A (zh) 2015-04-08
JP6173393B2 (ja) 2017-08-02
EP2826771A2 (en) 2015-01-21
NZ700818A (en) 2016-05-27
ES2553628T3 (es) 2015-12-10
US10463639B2 (en) 2019-11-05
MX356714B (es) 2018-06-11
US10398665B2 (en) 2019-09-03
EP2616444A2 (en) 2013-07-24
WO2012036573A3 (en) 2012-08-16
EP2826771A3 (en) 2015-02-18
IL235014A (en) 2017-10-31
CN103228632A (zh) 2013-07-31
CN104478800A (zh) 2015-04-01
US20130303761A1 (en) 2013-11-14
US10420738B2 (en) 2019-09-24
US20160095869A1 (en) 2016-04-07
AU2011302715B2 (en) 2016-08-04
WO2012036573A2 (en) 2012-03-22
CA2811265C (en) 2018-07-31
SI2616444T1 (sl) 2016-03-31
JP5926731B2 (ja) 2016-05-25
HUE026271T2 (en) 2016-05-30
EP2816034A2 (en) 2014-12-24
JP6284914B2 (ja) 2018-02-28
EP2826771B1 (en) 2018-12-12
IL235015A0 (en) 2014-11-30
US20160000778A1 (en) 2016-01-07
CA2811265A1 (en) 2012-03-22
PT2616444E (pt) 2015-12-09
EP2816034A3 (en) 2015-03-04
HRP20151224T1 (hr) 2016-01-01
MX2013002895A (es) 2013-06-05
JP2013537225A (ja) 2013-09-30
NZ609204A (en) 2015-05-29
KR20140023866A (ko) 2014-02-27
EP2816035A2 (en) 2014-12-24
CN104478882A (zh) 2015-04-01

Similar Documents

Publication Publication Date Title
IL235013A0 (en) Compounds as modulators of truncated cftr protein and their use in the treatment of diseases associated with cftr protein dysfunction
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
EP2665749A1 (en) Anti - il1rap antibodies and their use for treating human
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
EP2627331A4 (en) METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
AP2015008931A0 (en) Benzothiazole compounds and their pharmaceutical use
AP2014007533A0 (en) Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
WO2011140517A9 (en) Methods for treating diseases of the lung
ZA201301601B (en) Treatment of diseases
EP2591758A4 (en) Disposable diaper
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
GB201011411D0 (en) Therapeutic compounds and their use
ZA201208389B (en) Treatment of proliferative diseases
EP2538951A4 (en) Agents and mechanisms for treating hypercholesterolemia
GB201008877D0 (en) Biolgical control of molluscs
AU2011904672A0 (en) Therapeutic Compounds and Uses Thereof
PL392396A1 (pl) Modulatory funkcji zmutowanego białka CFTR oraz zastosowanie modulatorów w leczeniu chorób związanych z zaburzeniami w prawidłowym funkcjonowaniu białka CFTR
PL392397A1 (pl) Modulatory funkcji zmutowanego białka CFTR oraz zastosowanie modulatorów w leczeniu chorób związanych z zaburzeniami w prawidłowym funkcjonowaniu białka CFTR
HK1178089A (en) Treatment of proliferative diseases
AU2011902559A0 (en) Compounds and Therapeutic Applications Therefor
AU2011904831A0 (en) Apricitabine and PI combination therapy
HK1188955A (en) Methods for treating diseases of the retina
AU2011900677A0 (en) Therapeutic and diagnostic agents
HK1180536A (en) Animal models and therapeutic molecules